Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Capital Expenditures (2023 - 2025)

Monte Rosa Therapeutics' Capital Expenditures history spans 3 years, with the latest figure at $4.3 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 213.48% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $4.7 million, up 9300.0%, while the annual FY2025 figure was $4.7 million, 9300.0% up from the prior year.
  • Capital Expenditures reached $4.3 million in Q4 2025 per GLUE's latest filing, up from -$2.8 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $15.9 million in Q3 2023 to a low of -$17.1 million in Q4 2023.
  • Average Capital Expenditures over 3 years is $415583.3, with a median of $1.5 million recorded in 2024.
  • The largest YoY upside for Capital Expenditures was 213.48% in 2025 against a maximum downside of 812.53% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at -$17.1 million in 2023, then soared by 78.06% to -$3.8 million in 2024, then soared by 213.48% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Capital Expenditures are $4.3 million (Q4 2025), -$2.8 million (Q3 2025), and $1.7 million (Q2 2025).